Learn the GLP-1 weight loss category.

Plain-English summary of the FDA-approved Wegovy prescribing information: BMI thresholds, the boxed warning, contraindications, and breastfeeding guidance from the current label.

The headline price is rarely the real price. Here is the anatomy of the real monthly bill, and the hidden cost mechanisms used by every major program.

Compounded GLP-1s are the same molecule as Wegovy and Ozempic but a fundamentally different regulatory product. Here is the truth on safety, sourcing and why the cheap-tier era is ending.

Auto-renewal, free-trial conversion, non-refundable upfront, lock-in commitments, phone-only cancel, medication forfeit, dispute waiver. The full list of legal mechanisms programs use to keep your money.

Hims says no lock-in. WeightWatchers says 12 months. Found says 6-month non-refundable. The phrase has at least four real meanings, and the difference is thousands of dollars.

Novo Nordisk's exclusivity on semaglutide expires in stages from 2026. Here is the realistic timeline, the price implications, and which programs will move first.

Most commercial insurance now covers semaglutide and tirzepatide for obesity, but coverage is uneven. Here is how to figure out what you actually pay before you commit to a program.

Wegovy at 14.9% mean weight loss. Zepbound at 22.5%. Saxenda at 7.4%. The numbers behind every weight-loss program's marketing copy, and what they hide.

Nausea is the headline. The full picture from registration trials includes diarrhea, fatigue, gallstones and a few rare-but-serious events worth knowing about before you start.

Standard titration is one dose level every four weeks. The published schedule is a default, not a law. Here is what to do when the standard schedule does not fit your tolerance.

Most patients hit at least one weight loss stall on a GLP-1. Some are real, some are measurement noise, some signal a need to escalate. Here is how to tell which kind you are dealing with.

The data say yes for most patients. The economics, the side effects, and the long-term safety record are all evolving. Here is the state of play in 2026.

Ozempic and Wegovy are the same molecule. Mounjaro and Zepbound are the same molecule. The differences are in dose, indication, insurance coverage and what your prescription actually says.

Medicaid coverage for Wegovy, Zepbound and other GLP-1s varies wildly by state. The federal program does not require coverage for weight loss drugs, so each state's preferred drug list (PDL) decides. Here's the framework for finding out what your state covers and the broad pattern in 2026.

Zepbound shows higher mean weight loss in its registration trial. That does not mean it is the right pick for every patient. Here is what the head-to-head data actually says.

Insurance prior auth for Wegovy or Zepbound is the single most common reason patients give up on the brand route. Here is the exact path that works, what triggers a denial and how to appeal.

Compounded semaglutide can be 3-5x cheaper than brand Wegovy. Most patients who switch from compounded to brand do so for one of four specific reasons. Here is the decision framework.

The Reddit screenshots show dramatic month-1 losses. The trial data shows a more measured curve. Here is what to actually expect in months 1, 3, 6, 12 and 24 of GLP-1 treatment.

Most US primary care doctors can write a GLP-1 prescription. Most patients go to telehealth anyway. Here is when each path makes sense, and the four scenarios where PCPs win.

Most telehealth programs send the prescription and assume you know what to do. Here is the actual injection technique, dose-by-dose, with the four mistakes that cause 80% of side effects.

The peptide denatures above 30°C. The 14-28 day room-temperature window helps, but international flights, summer road trips and apartment heatwaves still require planning. Here is what works.

About 30% of the weight a typical GLP-1 patient loses is lean mass, including muscle. The number is real. Whether it matters depends on what you do alongside the medication.

Most patients describe the first 8-16 weeks as 'food noise turned off, weight falling effortlessly'. Then something shifts. The honeymoon is real, the cliff after it is also real and understanding both is the difference between long-term success and abandonment.

Most telehealth programs in our chart are legitimate. A few are racing to the bottom on price by cutting corners that matter. Here are the specific red flags worth checking before you sign up.

GLP-1 medications are evidence-based for PCOS, improving insulin sensitivity, menstrual regularity and weight. They are also contraindicated in pregnancy. For PCOS patients planning to conceive, the timing matters.

GLP-1 medications are contraindicated in pregnancy. If you just learned you are pregnant while on Wegovy, Zepbound, Ozempic or compounded semaglutide, this is what to do now.

GLP-1 medications are FDA-approved only for type 2 diabetes. Off-label use in type 1 diabetes is growing among adult patients on insulin pumps. The data is real but thin.

GLP-1 medications work in older adults. The trade-offs are different: sarcopenia risk is real, fall-risk implications matter and the optimal dose may be lower than the FDA maximum. Here is the senior-specific guidance.

Roughly 20-30% of bariatric surgery patients regain meaningful weight within 5 years. GLP-1 medications are effective for post-bariatric regain. The clinical considerations are different from first-line GLP-1 use.

Beyond NovoCare and LillyDirect, there are 503B compounding routes, manufacturer copay cards, 340B clinic access and assistance programs most patients never hear about. Here is the full map.

The SELECT trial enrolled 17,604 patients with established cardiovascular disease and showed a 20% relative-risk reduction in MACE on Wegovy 2.4mg weekly. For clinicians and healthcare-literate patients, here is the breakdown of what the trial actually showed and where the data is limited.

Most US telehealth programs require a Social Security Number at intake. For ITIN-holders, undocumented residents and patients with privacy concerns, three real paths exist. Here is what works and what doesn't.

Before paying $178-$549/month for a GLP-1, several cheaper options deserve a fair comparison. Berberine, metformin off-label and structured lifestyle programs all have evidence. Here is what they actually do and where GLP-1 still wins.

Most comparison sites in this category gloss over GLP-1 risks. This is the unvarnished review: pancreatitis signal, gallbladder events, gastroparesis, suicide ideation MHRA review outcome, Ozempic face, discontinuation patterns. Sourced from FAERS, NEJM and FDA labels.

The FLOW trial (3,533 patients, semaglutide 1.0 mg, T2D with CKD) showed a 24% relative-risk reduction in major kidney-disease events. For nephrology patients and their families, here is what the data actually says.

Most patients plateau by month 18-24 even on maximum dose. The next move is a real decision: switch to tirzepatide, add bupropion-naltrexone, intensify behavioral support or accept the new setpoint. Here is how the evidence breaks down.

If you're losing employer insurance, aging into Medicare, weighing COBRA or switching plans, this is the bridge playbook. Six scenarios with concrete cost math.

Vyvanse is the only FDA-approved medication for BED. GLP-1 is showing promise in pilot trials, with real risks alongside. Here is where things stand for BED patients considering GLP-1.

Microdose protocols claim 30-50% of the standard dose at 30-50% of the cost. The evidence is thin but not zero. Here is what the available data says and where the gaps are.

MHRA and EMA reviewed the 2023-2024 reports of suicidal ideation on GLP-1. The verdict was no causal link. Here is the data, the limits, and what patients on SSRIs should know.

In December 2024 FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. This changed insurance coverage and PA criteria for tens of thousands of patients. Here's what the indication means.

Patients on dialysis were excluded from the FLOW trial. Off-label use in ESRD is growing but evidence is thin. Here is what dosing and timing protocols obesity-medicine and nephrology specialists use.

Low-dose semaglutide is increasingly used as a healthspan intervention by Bryan-Johnson-curious patients. The evidence is speculative beyond established cardiometabolic indications. Here is where the evidence stands.

The PA decision is not a coin flip. Commercial plans run a checklist of BMI, comorbidity codes, prior-trial documentation and PBM-specific quirks. Here is the actual decision tree your plan is running.

Appetite returns inside the first month. Most patients regain 60 to 70 percent of lost weight within 12 months. The biology is well-documented, the tapering options are not. Here is the week-by-week timeline and the decision framework on whether to stop, taper or microdose.

Both drugs work. The 5-year cash bill varies by a factor of 10 depending on insurance, HSA use and which manufacturer direct program you route through. Here is the math, with worked examples for cash-pay, insurance-approved and HSA scenarios.

Week 1 is mostly side effects. Month 3 is when the scale moves enough to notice. Month 12 is where most patients land. Here is the granular timeline with what is typical, what is a red flag and what to discuss with your prescriber at each step.

Both are tirzepatide, and both are made by Lilly. But they cost different amounts and get treated differently by insurance, and the prescribing pathway isn't the same either. Here's why the two labels exist and how to tell them apart in 2026.

About 35 percent of initial GLP-1 prior authorizations are denied. About half of appeals succeed. The path to success depends on which denial reason you got, and which of the four escalation tiers you use. Here is what works and what to file at each step.

Patients with obstructive sleep apnea hear about GLP-1s and assume Wegovy qualifies. It does not. The OSA indication belongs to Zepbound, not Wegovy, and that single regulatory fact reshapes coverage, prior authorization and cash-pay strategy.

Tirzepatide produced histologic resolution of MASH in roughly 62 percent of patients in SYNERGY-NASH at 52 weeks. That is the largest effect any drug has shown in the disease. The catch: no current FDA indication, no payer coverage path under MASH, and a long road to label change.

Semaglutide improves insulin resistance, restores menstrual cycles, and meaningfully reduces weight in PCOS patients. It is also contraindicated in pregnancy and requires washout before conception. Here is how to plan the on-and-off timeline if fertility is the goal.

The SELECT trial proved a 20 percent reduction in major cardiovascular events on Wegovy in patients with established CVD and overweight. That result reshaped Medicare coverage in 2024. For secondary-prevention patients, the path to a covered prescription now runs through a cardiology-coded diagnosis, not a weight-loss claim.

Prediabetes affects 38 percent of US adults. Mounjaro reduced progression to type 2 diabetes by 94 percent in the SURMOUNT-1 prediabetes subgroup at 176 weeks. The catch: prediabetes is not an FDA indication, no insurance covers it under prediabetes, and the cash-pay floor sits near $1,069 per month.

FLOW showed a 24 percent reduction in major kidney events on semaglutide 1.0 mg weekly in T2D patients with CKD. The trial dose is the Ozempic dose, not the Wegovy dose. KDIGO updated its guideline. Coverage now flows through the T2D-plus-CKD pathway.

The SUMMIT trial showed tirzepatide reduced the composite of CV death and worsening heart-failure events by 38 percent in patients with HFpEF and obesity. The label changed. Cardiology is now in the GLP-1 conversation in a way it was not before.

Patients on GLP-1 medications report reduced alcohol cravings and lower consumption. The phase 2 trials are now reporting. The effect is real, but the evidence is still early, the indication does not exist, and the patient population the trials studied is narrow.

The SURPASS-2 trial put tirzepatide head to head with semaglutide in T2D. SURMOUNT-1 versus STEP-1 puts them side by side in obesity. The molecules are not interchangeable. Here is the data, the side-effect differences, and where insurance treats them differently.

List price is $1,349. Almost nobody pays it. Here are the four cash-pay routes a Wegovy patient can actually take, and what year one costs at each.

Zepbound and Mounjaro are both tirzepatide. The label, the insurance posture, and the cash-pay path are not. Here is when to ask for which.

Cancel the old program too early and you lose the prescription. Too late and you pay double. Here is the exact sequencing for a clean switch.

Past the shortage resolution and through two years of enforcement, here is the FDA position on compounded GLP-1s. With the agency quotes and the case data.

Six to nine months in, the scale stalls. Sometimes the answer is more dose. Sometimes a different molecule. Here is what the trial data says about which.

Wegovy 2.4 mg, Zepbound 15 mg, Ozempic 2 mg, Mounjaro 15 mg. Here is what maintenance means clinically, what the trial data says about dropping a step, and when to consider tapering.

Nine of the telehealth programs we track bundle compounded medication into the monthly fee. Here is the verified list with pricing, the nuances that matter, and how to compare total cost fairly against programs that charge separately.

Most GLP-1 telehealth programs let you cancel online with no fee. A handful do not, and the ones that bury a 12-month lock or a phone-only cancellation are the ones that cost people money. Here is the verified breakdown for all programs we track.

Both programs now sell branded Wegovy to new patients, but the all-in number is not the same. LifeMD lands around $224 a month at its cheapest maintenance path; Hims lands around $298. Here is exactly where the $74 gap comes from, and where each one is still the better buy.

The cheapest price that holds at every dose is $178 a month, flat, for the injectable. The $99 oral-lozenge sticker you may see advertised is an entry-dose price whose maintenance cost is not published. Two things separate a real low price from a teaser: dose tiering and supply risk. Here is the ranked list, with both spelled out.

Wegovy at full cash price runs $349 to $499 a month through NovoCare. Five paths get you the same clinical result for less. Here is what each route actually costs and what it requires.

Most first PA requests for Wegovy get denied, and most denials are never appealed. The gap between denial and approval is the denial reason: match your letter to the specific code the plan cited.

Ten programs in our chart accept insurance for GLP-1 weight loss. Here is how each one actually bills your plan, what you owe per month with coverage, and the catch for each.

A balanced read on the major 2025-era GLP-1 trials and cohorts: the cardiovascular, kidney, liver and cancer-signal wins, plus the Alzheimer's miss and the vision-risk question. What is randomized, what is only observational, and where each result does not generalize.

No GLP-1 is FDA-approved specifically for PCOS, but PCOS patients almost universally qualify via obesity or insulin resistance criteria. Tirzepatide produces more total weight loss; semaglutide has more PCOS-specific RCT data. Here is which drug to choose, which programs to use, and how to file for insurance coverage.

Tirzepatide costs more than compounded semaglutide at most programs, but not all. Mochi Health charges a flat $178 a month for its compounded GLP-1 program regardless of molecule. Below that, the numbers come with catches: minimum commitments, pricing-at-signup opacity, or 12-month lock-ins. Plus the regulatory risk specific to tirzepatide that the semaglutide list does not carry.

Starting July 1, 2026, Medicare Part D beneficiaries who meet CMS clinical criteria can get branded GLP-1s for a flat $50 a month under a demonstration running through December 2027. The eligibility paths are narrower than the headlines, the program excludes type 2 diabetes and sleep apnea prescriptions, and the $50 never counts toward your deductible or out-of-pocket totals. What CMS actually published, and what to do before July 1.

Compounded GLP-1s are made by a pharmacy, not the telehealth brand. How 503A and 503B pharmacies differ, what changed in 2026, how to vet one, and which programs name their pharmacy.

Whether your plan covers Wegovy or Zepbound depends on decisions made by your employer, not your insurer. Here is how to find out, what to ask HR, and why the answer varies so much.

Self-insured plans operate under federal ERISA law, not state insurance rules. That changes your appeal rights, timelines, and who has the final say.

Your employer controls the benefit design for a self-insured plan. That means you can ask them to add GLP-1 coverage or grant an exception. Here is what works and what does not.

Ozempic at a retail pharmacy without insurance costs nearly $1,000 a month. Telehealth cash routes start under $200. Here is exactly when each path wins.

People switch GLP-1s for cost, side effects, a stalled scale, or a coverage change. Some switches keep the same molecule and carry your dose over. Others restart titration from the lowest dose. Here is which is which, the washout question, and exactly what to ask your prescriber.